RxDoctor Payments Data

John Kim, MD

Ophthalmology · Colton, CANPI 1508050220

Payments from drug & device makers

$5,479in general payments, 2019–2025

Across 99 payments — averaging $55.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Alcon$380
  • Bausch & Lomb Americas Inc.$249
  • Johnson & Johnson Surgical Vision, Inc.$140
  • Aerie Pharmaceuticals, Inc.$136
  • Glaukos Corporation$110
  • plus $461 from 14 others

What the payments were for

  • Consulting fees$3,00055%
  • Travel & lodging$3687%
  • Food & beverage$2,08738%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,479 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$249,359
Medicare patients
633
Services billed
2,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate341$146,059
LumiganBimatoprost212$91,172
Alphagan PBrimonidine Tartrate109$30,287
Brimonidine Tartrate535$22,304
RestasisCyclosporine27$19,420
VyzultaLatanoprostene Bunod46$18,876
Latanoprost1,538$16,137
Cyclosporine35$13,605
Prednisolone Acetate320$12,653
RocklatanNetarsudil Mesylat/Latanoprost29$12,044
SimbrinzaBrinzolamide/Brimonidine Tart54$11,924
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat454$7,302
Travoprost28$5,813
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$5,254
Brinzolamide28$5,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$136$158,103370 claims
AbbVieLumigan, Alphagan P, Restasis$4,003$140,879348 claims
Bausch & Lomb Americas Inc.Vyzulta$249$18,87646 claims
AlconSimbrinza$380$11,92454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →